Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

3LK0

X-ray structure of bovine SC0067,Ca(2+)-S100B

3LK0 の概要
エントリーDOI10.2210/pdb3lk0/pdb
関連するPDBエントリー3LK1
分子名称Protein S100-B, CALCIUM ION, 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine, ... (4 entities in total)
機能のキーワードef hand, alpha helical, metal-binding, metal binding protein
由来する生物種Bos taurus (bovine)
細胞内の位置Cytoplasm: P02638
タンパク質・核酸の鎖数4
化学式量合計42617.20
構造登録者
Charpentier, T.H.,Weber, D.J.,Wilder, P.W. (登録日: 2010-01-26, 公開日: 2010-12-29, 最終更新日: 2024-05-22)
主引用文献Wilder, P.T.,Charpentier, T.H.,Liriano, M.A.,Gianni, K.,Varney, K.M.,Pozharski, E.,Coop, A.,Toth, E.A.,Mackerell, A.D.,Weber, D.J.
In vitro screening and structural characterization of inhibitors of the S100B-p53 interaction.
Int J High Throughput Screen, 2010:109-126, 2010
Cited by
PubMed Abstract: S100B is highly over-expressed in many cancers, including malignant melanoma. In such cancers, S100B binds wild-type p53 in a calcium-dependent manner, sequestering it, and promoting its degradation, resulting in the loss of p53-dependent tumor suppression activities. Therefore, S100B inhibitors may be able to restore wild-type p53 levels in certain cancers and provide a useful therapeutic strategy. In this regard, an automated and sensitive fluorescence polarization competition assay (FPCA) was developed and optimized to screen rapidly for lead compounds that bind Ca(2+)-loaded S100B and inhibit S100B target complex formation. A screen of 2000 compounds led to the identification of 26 putative S100B low molecular weight inhibitors. The binding of these small molecules to S100B was confirmed by nuclear magnetic resonance spectroscopy, and additional structural information was provided by x-ray crystal structures of several compounds in complexes with S100B. Notably, many of the identified inhibitors function by chemically modifying Cys84 in protein. These results validate the use of high-throughput FPCA to facilitate the identification of compounds that inhibit S100B. These lead compounds will be the subject of future optimization studies with the ultimate goal of developing a drug with therapeutic activity for the treatment of malignant melanoma and/or other cancers with elevated S100B.
PubMed: 21132089
DOI: 10.2147/IJHTS.S8210
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.04 Å)
構造検証レポート
Validation report summary of 3lk0
検証レポート(詳細版)ダウンロードをダウンロード

234440

件を2025-04-09に公開中

PDB statisticsPDBj update infoContact PDBjnumon